The top pharmaceutical companies to watch in 2026 are not simply the biggest by revenue. They are the companies whose approvals, patent expiries and pipeline decisions this year will reset positions in obesity, oncology, immunology and vaccines. Full-year 2026 results do not exist yet, so every figure below comes from the latest reported period: calendar-year 2025 results, plus first-half 2026 filings.
This is an analysis with a stated method, not an official ranking. The ten are Eli Lilly, Novo Nordisk, Johnson & Johnson, Merck & Co., AstraZeneca, Novartis, AbbVie, Pfizer, Daiichi Sankyo and Boehringer Ingelheim. Some are growing faster than companies of their size usually can. Others are here because 2026 is the year a patent cliff, a launch or a large acquisition either works or does not.
How We Selected the Pharmaceutical Companies to Watch in 2026
Largest and most worth watching are different questions. Ranked by FY2025 pharmaceutical-segment revenue, the leaders were Eli Lilly, Merck, Pfizer, AbbVie, Johnson & Johnson Innovative Medicine, AstraZeneca, Roche, Novartis, Sanofi and Bristol Myers Squibb (Drug Discovery & Development, Pharma 50 2026). That answers who is biggest, not where 2026 is decided. For a US view of scale, see our guide to the largest pharmaceutical companies headquartered in the United States.
We weighed seven factors against each other rather than scoring them, because comparable data does not exist for every company:
- Reported performance: latest full-year revenue and most recent 2026 quarter
- R&D investment, absolute and as a share of revenue
- Approvals and launches during 2025 and 2026
- Pipeline catalysts and readouts landing inside 2026
- Loss-of-exclusivity exposure, and the answer to it
- Acquisitions and licensing that change the pipeline
- Alignment with the forces reshaping the industry: incretins, antibody-drug conjugates, radioligand therapy, AI and pricing policy
Roche, Sanofi, Bristol Myers Squibb, GSK, Amgen, Vertex, Takeda and Regeneron narrowly missed: their defining catalysts sit outside 2026 or repeat a story already here. Revenue appears as each company reports it, in its own currency and fiscal calendar.
Top 10 Pharmaceutical Companies to Watch in 2026
The table compares reported scale and research intensity. Profiles follow, in no ranked order.
| Company | Headquarters | Latest full-year revenue | R&D, same period |
|---|---|---|---|
|
1. Eli Lilly |
Indianapolis, USA |
$65.2B (FY2025, +45%) |
$13.3B |
|
2. Novo Nordisk |
Bagsværd, Denmark |
DKK 309.1B (FY2025, +10% CER) |
DKK 52.0B (16.8%) |
|
3. Johnson & Johnson |
New Brunswick, USA |
$94.2B (FY2025, +6.0%) |
$14.7B (15.6%) |
|
4. Merck & Co. |
Rahway, USA |
$65.0B (FY2025, +1%) |
$15.8B |
|
5. AstraZeneca |
Cambridge, UK |
$58.7B (FY2025, +8% CER) |
$13.8B core (24%) |
|
6. Novartis |
Basel, Switzerland |
$54.5B (FY2025, +8%) |
$11.2B |
|
7. AbbVie |
North Chicago, USA |
$61.2B (FY2025, +8.6%) |
$9.1B (14.9%) |
|
8. Pfizer |
New York, USA |
$62.6B (FY2025, −2%) |
$10.4B |
|
9. Daiichi Sankyo |
Tokyo, Japan |
¥2,123.0B (FY to Mar 2026, +12.6%) |
¥462.1B |
|
10. Boehringer Ingelheim |
Ingelheim, Germany |
€27.8B (FY2025, +7.3% CER) |
€6.4B (22.9%) |
1. Eli Lilly and Company
Indianapolis, USA. Cardiometabolic, oncology, immunology, neuroscience. FY2025 revenue was $65.2 billion, up 45%, and Q2 2026 alone reached $23.0 billion. Mounjaro and Zepbound produced roughly $36.5 billion. In April 2026 the FDA approved Foundayo (orforglipron), the first oral small-molecule GLP-1 for weight management. R&D reached $13.3 billion, supported by a $1 billion co-innovation lab with NVIDIA. Lilly holds both the leading injectable incretin franchise and an approved oral GLP-1, so its 2026 constraint is manufacturing scale, not demand.
2. Novo Nordisk
Bagsværd, Denmark. Diabetes, obesity, rare disease. FY2025 net sales were DKK 309.1 billion, up 10% at constant currency, with R&D at 16.8% of sales. Novo won FDA approval for oral Wegovy and passed 265,000 weekly US prescriptions by mid-July 2026. It is also mid-restructuring: a new chief executive, 9,000 job cuts, a DKK 4.0 billion monlunabant impairment, a missed ziltivekimab endpoint and a CagriSema filing under review. It is the only company of this size guiding to a full-year contraction.
3. Johnson & Johnson
New Brunswick, USA. Oncology, immunology, neuroscience, cardiovascular, MedTech. FY2025 sales were $94.2 billion, up 6.0%, of which Innovative Medicine was $60.4 billion; R&D was $14.7 billion. Stelara fell 41.3% as biosimilars arrived, while Darzalex grew 23.0% to $14.4 billion. Two novel launches followed in 2026: Icotyde, an oral IL-23 peptide for psoriasis, and Inlexzo for BCG-unresponsive bladder cancer. J&J also intends to separate its orthopaedics business while guiding to its first year above $100 billion.
4. Merck & Co. (MSD)
Rahway, USA. Oncology, vaccines, cardiometabolic, animal health. FY2025 sales were $65.0 billion, up 1%, with Keytruda at $31.7 billion, Gardasil down 39% and R&D of $15.8 billion. Ahead of Keytruda’s 2028 exclusivity loss, Merck bought Verona Pharma for about $10 billion, Cidara, and Terns Pharmaceuticals for $6.7 billion. Two diversifiers are live: Lipfendra (enlicitide), the FDA’s first once-daily oral PCSK9 inhibitor, and Winrevair, up 75% in Q2 2026.
5. AstraZeneca
Cambridge, UK. Oncology, cardiometabolic, respiratory and immunology, rare disease, vaccines. FY2025 total revenue was $58.7 billion, up 8% at constant currency, with core R&D of $13.8 billion, about 24% of revenue, the highest intensity here. H1 2026 revenue reached $30.7 billion. It began direct NYSE trading in February 2026 while keeping its UK headquarters, and is committing $50 billion in the US by 2030 plus $15 billion in China. Baxfendy (baxdrostat), a first-in-class hypertension drug, was approved in May 2026.
6. Novartis
Basel, Switzerland. Cardiometabolic, immunology, neuroscience, oncology, radioligand therapy. FY2025 net sales were $54.5 billion, up 8%, with R&D of $11.2 billion. Entresto, a $7.7 billion product in FY2025, fell 50% at constant currency in Q2 2026 after losing US exclusivity, and Novartis guides to low-single-digit growth for 2026. Against that: Kisqali up 43%, Scemblix up 89%, a $12 billion acquisition of Avidity Biosciences, and Pluvicto approved in July 2026 in hormone-sensitive prostate cancer, roughly doubling its eligible population.
7. AbbVie
North Chicago, USA. Immunology, oncology, neuroscience, aesthetics, eye care. FY2025 net revenues were $61.2 billion, up 8.6%, with R&D of $9.1 billion and neuroscience up 19.6%. In Q2 2026 Humira fell to $756 million, down 36% operationally, while Skyrizi and Rinvoq together delivered about $8.0 billion in that quarter. AbbVie completed a $10.9 billion acquisition of Apogee Therapeutics and trimmed 2026 guidance purely for deal dilution. It is the clearest example of a company already past a mega-blockbuster cliff.
8. Pfizer
New York, USA. Internal medicine, inflammation and immunology, vaccines, oncology. FY2025 revenues were $62.6 billion, down 2% but up 6% operationally excluding COVID-19 products; R&D was $10.4 billion. Paxlovid fell 59% in FY2025, then 95% operationally in Q2 2026. Pfizer answered with a $10 billion acquisition of Metsera, won against Novo Nordisk, and a July 2026 Innovent deal worth $650 million upfront for 12 oncology candidates. Watch berobenatide, a potential monthly GLP-1 peptide entering ten Phase 3 studies this year.
9. Daiichi Sankyo
Tokyo, Japan. Antibody-drug conjugate oncology, cardiovascular, pain. Revenue for the year ended March 2026 was ¥2,123.0 billion, up 12.6%, with R&D of ¥462.1 billion. Enhertu, partnered with AstraZeneca, reached ¥698.4 billion, up 26.3%, and the company has raised its full-year projection above ¥1 trillion. Datroway grew 146.2% and became the first TROP2 ADC approved in the US in first-line metastatic triple-negative breast cancer. Five ADC launches are planned across 2026. One caveat: about ¥29 billion of SG&A was omitted from the FY2025 report, so profit figures may be restated.
10. Boehringer Ingelheim
Ingelheim am Rhein, Germany. Cardiometabolic, respiratory, immunology, oncology, animal health. Privately held. FY2025 net sales were €27.8 billion, up 7.3% currency-adjusted, with R&D of €6.4 billion, or 22.9% of sales, and Jardiance alone at €8.8 billion. H1 2026 group sales grew 16.2% and Human Pharma grew 20.1% on two 2025 launches: Hernexeos for HER2-mutant lung cancer and Jascayd for pulmonary fibrosis. Survodutide, its GLP-1/glucagon dual agonist, produced positive Phase 3 data in H1 2026.
Pharmaceutical Industry Trends to Watch in 2026
Six forces sit behind most of the profiles above. For the marketing-side view, see our overview of B2B pharmaceutical industry trends.
- Approvals are running ahead. FDA’s drug centre listed 37 novel approvals as of 3 September 2026, against 46 in all of 2025 and 50 in 2024. The EMA recommended 38 new active substances in 2025.
- A patent cliff larger than 2011-12. IQVIA forecasts global medicine spending above $2.6 trillion by 2030, growing 5% to 8% a year, and puts brand losses from expiries near $200 billion. Both are forecasts, not results.
- Dealmaking has accelerated. First-half 2026 biopharma M&A reached about $134 billion across 33 deals of $1 billion or more, against roughly $112 billion in all of 2025.
- Obesity is a multi-company race. Oral GLP-1s are approved on both sides of the Lilly and Novo rivalry, while Amgen, Boehringer, AstraZeneca and Pfizer all have Phase 3 entrants.
- China is now an originator. Hengrui reports about $42 billion of overseas deal value since 2023, and GSK signed a deal worth up to roughly $12 billion for 12 of its assets.
- ADCs, radioligand therapy and AI reached scale. Enhertu is tracking above ¥1 trillion, Pluvicto won a population-doubling label, and the FDA launched Elsa 4.0 and its HALO platform in May 2026 while its AI guidance remains draft.
- Policy is now a pipeline variable. CMS selected 15 drugs for the third Medicare negotiation cycle in January 2026, including Part B drugs for the first time, and Section 232 pharmaceutical tariffs took effect with relief tied to most-favored-nation pricing deals.
What These Pharmaceutical Companies Mean for the Healthcare Market
Four patterns repeat across all ten companies, and they generalise past pharma.
- Reformulation is a moat. Oral GLP-1s, an oral PCSK9 inhibitor, an oral IL-23 peptide and subcutaneous PD-1 all arrived inside eighteen months, extending franchises that new molecules could not.
- Cliffs are planned for, not reacted to. AbbVie and Novartis mark the two ends: one has replaced lost revenue, the other is being tested now.
- Capital buys pipeline, not only capacity. Licensing and bolt-on deals now supply much of the late-stage pipeline, increasingly from China.
- Policy is a product decision. Tariff relief tied to pricing agreements has moved tens of billions of dollars of manufacturing plans.
For vendors, buying centres inside these organisations are shifting toward launch operations, manufacturing build-out and regulatory data work, a pattern visible across the Fortune 500 pharmaceutical companies more broadly.
How Pharmaceutical Market Intelligence Supports B2B Healthcare Marketing
Industry intelligence answers which organisations matter. Campaigns need to know who to speak to inside them, a different data problem. A company profile tells you AstraZeneca is building in Virginia and Indiana. It does not tell you which clinical operations, regulatory affairs or manufacturing leaders own the decision.
Useful segmentation for a pharma target account list combines organisation, function, seniority, therapeutic area and geography, then keeps each record current, because reorganisations after an acquisition invalidate contact data fast. It is why multi-channel marketing in the pharmaceutical industry depends more on data hygiene than channel choice.
MedicoLeads builds verified healthcare and life-sciences contact data for that step. If you are mapping this market, our team can assemble a customized database around your target accounts and functions, or start with our guidance on reaching pharma decision-makers across the USA.
This article is general market information drawn from public filings and regulator publications. It is not investment, legal or regulatory advice.
Frequently Asked Questions
Who is the largest pharmaceutical company in the world in 2026?
It depends on the measure. By total FY2025 corporate revenue, Johnson & Johnson led at $94.2 billion, but that includes MedTech. By pharmaceutical-segment revenue, Eli Lilly led at $65.2 billion, just ahead of Merck at $65.0 billion.
What is the difference between the largest pharmaceutical companies and the ones to watch?
Size measures what a company already sells. A watchlist measures what is about to change: approvals landing this year, patent expiries hitting revenue, acquisitions being integrated, readouts due. A very large company can have a quiet year, and a mid-sized one a decisive year.
Which pharmaceutical companies are facing patent cliffs in 2026?
Novartis is absorbing the Entresto expiry, a $7.7 billion product in FY2025 that fell 50% at constant currency in Q2 2026. Johnson & Johnson is working through Stelara biosimilars, AbbVie through Humira, Amgen through denosumab, and Merck is preparing for Keytruda in 2028.
Are there approved oral GLP-1 weight-loss drugs in 2026?
Yes. The FDA approved Eli Lilly’s Foundayo (orforglipron) on 1 April 2026, the first oral small-molecule GLP-1 for weight management, with 12.4% mean weight reduction at the top dose in ATTAIN-1. Novo Nordisk’s oral Wegovy is also approved.
How many new drugs has the FDA approved in 2026?
FDA’s Center for Drug Evaluation and Research listed 37 novel drug approvals as of 3 September 2026, against 46 in all of 2025 and 50 in 2024. That excludes cell, gene and vaccine products.
Which large pharmaceutical companies are privately held?
Boehringer Ingelheim is the largest privately held company here, with €27.8 billion in FY2025 net sales and no quarterly guidance obligation. Servier and LEO Pharma are other non-listed European manufacturers. Private ownership funds long research cycles without earnings pressure.
How is AI being used in pharmaceutical R&D in 2026?
On both sides of the process. Eli Lilly built a $1 billion co-innovation lab with NVIDIA, Novartis works with Isomorphic Labs, and Bristol Myers Squibb deployed an AI assistant to over 30,000 employees. The FDA launched Elsa 4.0 and its HALO data platform in May 2026.
Why are Western pharmaceutical companies licensing drugs from China?
Speed and cost. Chinese biotechs out-licensed roughly $137.7 billion in deal value across 186 transactions during 2025, and China now accounts for close to 90% of global ADC licensing activity. GSK, Bristol Myers Squibb, AstraZeneca, Pfizer and Takeda have all sourced assets this way.
Final Thoughts
The pharmaceutical companies to watch in 2026 share one trait: something specific is being settled this year. Lilly is scaling an oral GLP-1. Novartis is testing whether launches cover a cliff. Merck is spending against a 2028 deadline. Daiichi Sankyo is running five ADC launches at once.
Full-year 2026 results arrive in early 2027. Until then, treat guidance as guidance and check any figure against the company’s own filing.